Xiaoming Ouyang

ORCID: 0000-0002-6632-3190
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Lung Cancer Treatments and Mutations
  • Cancer Cells and Metastasis
  • Cancer Research and Treatments
  • HER2/EGFR in Cancer Research
  • Cancer-related Molecular Pathways
  • RNA Interference and Gene Delivery
  • CAR-T cell therapy research
  • Immunotherapy and Immune Responses
  • Nonmelanoma Skin Cancer Studies
  • Hepatitis C virus research
  • interferon and immune responses
  • Cytomegalovirus and herpesvirus research
  • Advanced biosensing and bioanalysis techniques
  • Colorectal Cancer Treatments and Studies
  • Monoclonal and Polyclonal Antibodies Research
  • Liver Disease Diagnosis and Treatment
  • AI in cancer detection
  • Cancer-related gene regulation
  • Multiple Sclerosis Research Studies
  • Radiomics and Machine Learning in Medical Imaging
  • Lymphoma Diagnosis and Treatment
  • Virus-based gene therapy research
  • Colorectal Cancer Screening and Detection
  • Reconstructive Facial Surgery Techniques
  • Peripheral Neuropathies and Disorders

Oregon Health & Science University
2015-2024

Second Affiliated Hospital of Guangzhou Medical University
2008-2023

Guangzhou Medical University
2008-2023

Stanford University
2019-2021

Cardiovascular Institute of the South
2019-2021

ShenZhen People’s Hospital
2010

Changsha Medical University
2001

Deep learning (DL) can accelerate the prediction of prognostic biomarkers from routine pathology slides in colorectal cancer (CRC). However, current approaches rely on convolutional neural networks (CNNs) and have mostly been validated small patient cohorts. Here, we develop a new transformer-based pipeline for end-to-end biomarker by combining pre-trained transformer encoder with network patch aggregation. Our approach substantially improves performance, generalizability, data efficiency,...

10.1016/j.ccell.2023.08.002 article EN cc-by Cancer Cell 2023-08-30

Background Kin17 is ubiquitously expressed at low levels in human tissue and participates DNA replication, repair cell cycle control. Breast cancer cells are characterized by enabling replicative immortality accumulated damage. However, whether kin17 contributes to breast carcinogenesis remains unknown. Methodology/Principal Findings In this study, we show for the first time that an important molecule related cancer. Our results expression was markedly increased clinical tumors associated...

10.1371/journal.pone.0025343 article EN cc-by PLoS ONE 2011-09-29

Kin17 DNA and RNA binding protein (Kin17) is a highly conserved that participates in replication, repair cell cycle progression. Recently, the tumor-promoting function of has been demonstrated increasingly studied. In present study, role invasion metastasis non-small cells lung cancer (NSCLC) was investigated. Elevated mRNA expression identified total 97 NSCLC benign lesion tissue specimens. overexpression significantly correlated with high tumor grade lymph node metastasis, indicating poor...

10.3892/ol.2017.5707 article EN Oncology Letters 2017-02-09

Head and neck squamous cell carcinoma (HNSCC) currently only has one FDA-approved cancer intrinsic targeted therapy, the epidermal growth factor receptor (EGFR) inhibitor cetuximab, to which approximately 10% of tumors are sensitive. In order extend therapy options, we subjected patient-derived HNSCC cells small-molecule siRNA screens, first, find effective combination therapies with an EGFR inhibitor, second, determine a potential mechanistic basis for repurposing FDA approved agents HNSCC....

10.1080/15384047.2018.1451285 article EN Cancer Biology & Therapy 2018-06-01

The aim of the present study was to investigate magnetic resonance (MR) features meningeal solitary fibrous tumors (SFTs) in order improve their recognition. retrospectively analyzed MR manifestations 12 cases SFTs confirmed by surgery. lesions were terms site growth, growth mode, morphology, size, changes signal and edge focus. malignant 3 cases, benign 7 borderline 2 cases. A total spanned tentorium cerebelli, falx another case close falx. Overall, 4 superficial accompanied adjacent bony...

10.3892/ol.2018.8426 article EN Oncology Letters 2018-04-04

Here, a series of half-sandwich arene Ru(II) complexes with difluorinated ligands [Ru(η6-arene)(L)Cl] (L1 = 2-(2,3-difluorophenyl)imidazole[4,5f][1,10]-phenanthroline; L2 2-(2,4-difluorophenyl)imidazole[4,5f][1,10]-phenanthroline; benzene, toluene, and p-cymene) were synthesized characterized. Molecular docking analysis showed that these bind to c-myc G-quadruplex DNA through either groove binding or π-π stacking, the relative site in main ligand plays role regulating mode. The behavior was...

10.3390/molecules27061897 article EN cc-by Molecules 2022-03-15

Although cutaneous squamous cell carcinoma (cSCC) is treatable in the majority of cases, deadly invasive and metastatic cases do occur. To date there are neither reliable predictive biomarkers disease progression nor FDA-approved targeted therapies as standard care. address these issues, we screened patient-derived primary cultured cells from invasive/metastatic cSCC with 107 small-molecule inhibitors. In-house bioinformatics tools were used to cross-analyze drug responses DNA mutations...

10.1101/mcs.a005439 article EN Molecular Case Studies 2020-08-01

Posterior limb of the internal capsule lesions (PLICL) are one MRI features neuromyelitis optica spectrum disorder (NMOSD). However, there is no evidence that such pathogenically related to NMOSD. We retrospectively analyzed PLICL in NMOSD, and other central nervous system inflammatory disorders, 561 patients. also examined pathological samples six Of patients investigated, were found 65 (11.6%). Lesions bilateral 26 cases (40%) unilateral 39 (60%). Unilateral mainly located on left side...

10.1080/01616412.2017.1298230 article EN Neurological Research 2017-03-06

Abstract Background: HNSCC is the sixth most common cancer worldwide. EGFR overexpressed in up to 90% of and associated with poor outcome. An monoclonal antibody only approved molecular targeted therapy for HNSCC, however, resistance eventually occurs all patients. Methods: Functional screens including a small-molecule kinase inhibitor panel an RNAi screen were used identify agents that synergized inhibitors reducing cell viability patient-derived tumor cells. Effective combination therapies...

10.1158/1538-7445.am2017-1212 article EN Cancer Research 2017-07-01

HNSCC is the sixth most common cancer worldwide. EGFR overexpressed in up to 90% of and associated with poor outcome. An monoclonal antibody, cetuximab, was only approved molecular targeted therapy for HNSCC; however, resistance eventually occurs all patients. Functional screens including a small-molecule kinase inhibitor were used identify agents that synergized inhibitors reducing viability patient-derived tumor cells. Effective combination therapies validated scale-up experiments, their...

10.1158/1557-3265.aacrahns17-78 article EN 2017-11-30
Coming Soon ...